Table 3.
Outlets with specific anti-malarial categories as a percentage of outlets with at least one anti-malarial in stock, by sector¹
| Benin | DRC | Madagascar | Nigeria | Uganda | Zambia | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public/Not- for-Profit | Private | Public/Not- for-Profit | Private | Public/Not- for-Profit | Private | Public/Not- for-Profit | Private | Public/Not- for-Profit | Private | Public/Not- for-Profit | Private | |
| N=212 | N=632 | N=134 | N=1, 240 | N=560 | N=1, 854 | N=249 | N=1, 864 | N=534 | N=691 | N=176 | N=259 | |
| Any ACT | 71.4 a | 6.4 b | 84.4 a | 52.7 b | 92.2 a | 8.4 b | 60.6 a | 36.7 a | 81.5 a | 20.1 b | 82.2 a | 19.3 b |
| First-line quality-assured ACT | 66.4 a | 5.7 b | 75.8 a | 24.5 b | 91.9 a | 7.9 b | 49.2 a | 25.3 b | 73.4 a | 7.8 b | 81.5 a | 16.3 b |
| Quality-assured ACT | 66.4 a | 5.9 b | 78.7 a | 29.0 b | 91.9 a | 8.1 b | 49.2 a | 26.1 a | 73.4 a | 8.1 b | 81.5 a | 16.3 b |
| Non-Quality-assured ACT | 5.1 a | 0.5 b | 5.6 a | 23.6 b | 0.3 a | 0.3 a | 11.5 a | 10.5 a | 9.3 a | 15.2 a | 0.8 a | 2.9 b |
| Any non-artemisinin therapy | 96.7 a | 99.7 b | 93.8 a | 97.8 a | 36.3 a | 99.3 b | 81.7 a | 98.2 b | 68.6 a | 99.6 b | 98.4 a | 98.8 a |
| Chloroquine | 9.3 a | 82.1 b | 0.0 a | 4.0 b | 1.6 a | 95.5 b | 57.7 a | 91.9 b | 15.5 a | 61.0 b | 0.0 a | 21.7 b |
| SP | 51.2 a | 15.8 b | 66.9 a | 57.9 a | 22.0 a | 9.2 a | 62.7 a | 78.3 a | 49.9 a | 68.2 a | 65.5 a | 80.2 a |
| Quinine | 92.5 a | 24.0 b | 85.7 a | 84.3 a | 23.3 a | 10.7 a | 20.0 a | 9.2 a | 59.0 a | 82.9 b | 89.1 a | 16.8 b |
| Quinine injection | 60.0 a | 8.0 b | 65.6 a | 40.7 b | 20.9 a | 9.5 a | 19.0 a | 0.6 b | 56.4 a | 32.6 a | 51.2 a | 8.7 b |
| Oral artemisinin monotherapy | 3.8 a | 0.7 a | 10.2 a | 40.5 b | 0.0 a | < 0.1 a | 4.1 a | 45.1 b | 1.3 a | 13.3 b | 1.1 a | 2.5 a |
¹Statistical comparisons conducted across outlet types, within countries. Statistical difference is labelled with a superscript, a or b. Proportions with different letters in their superscripts differ significantly from one another within countries (p < 0.05 for all tests).